Cerevance Media Center
Solengepras Leads the Shift Beyond Dopamine
Current News
October 24, 2017
Trailblazer in Molecular Genetics and Neuroscience, Jeremy Nathans, M.D., Ph.D., to Advise Cerevance
Dr. Nathans is Professor of Molecular Biology and Genetics, Neuroscience and Ophthalmology at the Johns Hopkins University School of Medicine in Baltimore, Maryland, where his research focuses on molecular mechanisms of visual system development, function, and disease. He is also an Investigator in the Howard Hughes Medical Institute.
October 17, 2017
Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University
Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has signed an agreement with The Rockefeller University to license a novel technology for profiling specific cell populations in human brain tissue
October 12, 2017
Harvard’s Rudolph Tanzi, Ph.D., a Leader in Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board
Cerevance, a drug discovery and development company focused on brain diseases, today announced that Rudolph Tanzi, Ph.D., has joined the company as a senior-level scientific advisor.
October 5, 2017
Stanford Neuroscientist, Robert Malenka, M.D., Ph.D., to Advise Cerevance
Cerevance, a drug discovery and development company, today announced that Robert Malenka, M.D., Ph.D., has joined the company as a senior-level scientific advisor. Dr. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences at Stanford University.
News Archive
October 7, 2026
Cerevance to Present Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease
- Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2
- Statistically significant improvements in secondary endpoints of ON time without troublesome dyskinesia and motor experiences of daily living (MDS-UPDRS Part II)
- Improvements in daytime sleepiness (Epworth Sleepiness Scale) and quality of life (PDQ-39, exploratory) point to broad motor and non-motor benefit
- Generally well tolerated, with fewer adverse events than those typically associated with dopaminergic adjunctive therapies, and a discontinuation rate similar to placebo
- Cerevance to meet with FDA to discuss the path to a potential New Drug Application
February 23, 2026
Cerevance to Participate in the TD Cowen 46th Annual Health Care Conference
December 1, 2025
Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference
November 24, 2025
Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
Events Archive
October 30, 2026

A Binding Site for CVN293 Reveals a Mechanism for Allosteric Control of THIK-1 K2P Channel Gating
February 4, 2026

Discovery of Potent, Selective and Brain-Penetrant Small Molecule CD38 Inhibitors
October 21, 2024
CVN424, a GPR6 Inverse Agonist, for Parkinson’s Disease and Motor Fluctuations: A Double-Blind, Randomized, Phase 2 Trial
June 30, 2021




